- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07937852
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)
A Multicenter, Single Arm, Open-label, Extension, Roll-over Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis
The primary purpose of this study is to evaluate the long-term safety of fenebrutinib in participants with MS who were previously enrolled in one of the eligible Roche-sponsored parent studies, including, but not limited to FENhance I (NCT04586010), FENhance II (NCT04586023), FENtrepid (NCT04544449), and FENopta (NCT05119569).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Sauvegarde des contacts de l'étude
- Nom: Reference Study ID Number: CN45787 https://forpatients.roche.com/ No attachments to email below.
- Numéro de téléphone: 888-662-6728
- E-mail: global-roche-genentech-trials@gene.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Previous eligibility and participation in the open-label extension (OLE) phase of an eligible Roche-sponsored parent study, where the participant is receiving fenebrutinib as an investigational medicinal product (IMP)
- Minimum of 24 weeks exposure to open-label fenebrutinib in parent study
- Ability and willingness to comply with all aspects of the protocol including completion of procedures, interviews, questionnaires, assessments for the duration of the study
Exclusion Criteria:
- Concurrent participation in any clinical trial (other than the parent study). Participants who withdrew from fenebrutinib treatment in their respective parent study should also be excluded
- Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required
- Chronic liver disease unless considered stable for >6 months
- Acute liver disease
- Cirrhosis (Child-Pugh Class A, B, or C)
- Gilbert's syndrome
- Aspartate aminotransferase (ALT) or alanine aminotransferase (AST) > 1.5 × upper limit of normal (ULN)
- Total bilirubin greater than 1.5 × ULN
- A "yes" on any item of the Suicidal Behavior section of the Columbia-Suicide Severity Rating Scale (C-SSRS) or significant risk of a suicide, in the investigator's judgment
Note: Other protocol-defined inclusion/exclusion criteria may apply
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Fenebrutinib
Participants receiving fenebrutinib in OLE of their parent study may be eligible for enrollment in this extension study. Participants will continue fenebrutinib treatment at the dosage and route of administration received at the time of rollover from the parent study. |
Fenebrutinib will be administered as per the schedule specified in the protocol.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Number of Participants With Adverse Events (AEs)
Délai: Up to approximately 2 years
|
Up to approximately 2 years
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Change in Expanded Disability Status Scale (EDSS) Score Over Time
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in 9-hole Peg Test (9-HPT) Over Time
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Timed 25-foot Walk Test (T25FWT) Over Time
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of Composite 24-week Confirmed Disability Progression (cCDP24)
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of 24-week Confirmed Disability Progression (CDP24)
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of Modified cCDP24
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of 24-week Confirmed Disability Improvement (CDI24)
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Number of New or Enlarging T2 Magnetic Resonance Imaging (MRI) Lesions
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Number of T1 Hypointense MRI Lesions
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Volume of T2 Lesions
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Volume of T1 Hypointense Lesions
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Brain Volume
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Annualized Relapse Rate (ARR) (for Relapsing Multiple Sclerosis [RMS] Participants Only)
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Patient-reported Outcome Measure Information System/Quality of Life in Neurological Disorders - Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a) Over Time
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Multiple Sclerosis Impact Scale - 29-item (MSIS-29), Version 2 Physical Scale Over Time
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in MSIS-29 Psychological Scale Over Time
Délai: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Clinical Trials, Hoffmann-La Roche
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CN45787
- 2026-526037-26-00 (Ctis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .